EUVIMEDEUVIMED entdecken
Historischer Beitrag

Four Decades of Orphan Drugs and Priorities for the Future

Michael S Sinha iD, Ariel D Stern iD, Arti K Rai

New England Journal of Medicine · 2024

DOI: 10.1056/nejmp2401487 ↗

Kurz gefasst

Historischer Beitrag in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Michael S Sinha und 2 weiteren Autor:innen. Beteiligte Einrichtung: From the Center for Health Law Studies, Saint Louis University School of Law, St. Louis (M.S.S.); Harvard Business School and the Harvard-MIT Center …. Hauptthemen laut MEDLINE: Orphan Drug Production, Rare Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orphan Drug ProductionRare DiseasesHumansDrug ApprovalDrug IndustryHistory, 20th CenturyHistory, 21st CenturyUnited StatesUnited States Food and Drug Administration

Autor:innen und Institutionen

  • From the Center for Health Law Studies, Saint Louis University School of Law, St. Louis (M.S.S.); Harvard Business School and the Harvard-MIT Center for Regulatory Science - both in Boston (A.D.S.); Hasso Plattner Insti…

ORCID-Profile: Michael S Sinha, Ariel D Stern

Zitieren

APA

Sinha, M. S., Stern, A. D., & Rai, A. K. (2024). Four Decades of Orphan Drugs and Priorities for the Future. New England Journal of Medicine. https://doi.org/10.1056/nejmp2401487

Vancouver

Sinha MS, Stern AD, Rai AK. Four Decades of Orphan Drugs and Priorities for the Future. New England Journal of Medicine. 2024. doi:10.1056/nejmp2401487

BibTeX
@article{Sinha2024,
  author = {Sinha, Michael S and Stern, Ariel D and Rai, Arti K},
  title = {Four Decades of Orphan Drugs and Priorities for the Future},
  journal = {New England Journal of Medicine},
  year = {2024},
  doi = {10.1056/nejmp2401487}
}
Kostenlos starten →